Polaris Market Research has published its latest research report titled "U.S. Dupixent Market Size, Share, Trends, Industry Analysis Report By Indication [Atopic Dermatitis (AD), Asthma, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)], By Distribution Channel – Market Forecast, 2025 - 2034". The report examines the U.S. Dupixent Market, covering its current size, market share, growth prospects, and industry developments. It discusses the factors influencing demand and provides an overview of the changes taking place across the industry.

The study covers the market across the United States. It considers developments in the pharmaceutical and healthcare industries, changing patient requirements, and factors affecting business activity. The research also looks at the challenges faced by market participants and areas where new business opportunities may emerge.

The report draws on primary and secondary research to assess the market. It considers economic conditions, technological developments, regulatory requirements, and other factors relevant to the industry. The findings offer useful information to pharmaceutical companies, investors, healthcare providers, and other stakeholders assessing the market.

Market Size and Forecast

The U.S. Dupixent market size was valued at USD 11.04 billion in 2024 and is projected to reach USD 19.25 billion by 2034, growing at a CAGR of 5.70% during the forecast period from 2025 to 2034. The market size is estimated at USD 11.66 billion in 2025.

The report includes historical data from 2020 to 2023 and future estimates from 2025 to 2034 to show how the market is expected to develop during the forecast period.

Market Dynamics

Several factors influence the direction of the U.S. Dupixent Market. The report considers the following areas to understand their effect on market activity:

Supply and Demand: The report examines the growing demand for Dupixent due to the rising prevalence of type 2 inflammatory diseases, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. The increasing number of patients requiring advanced biologic treatments and the expansion of FDA-approved indications are supporting market demand. Improved insurance coverage and patient assistance programs are also contributing to greater treatment accessibility across the United States.

Technological Advancements: The study covers developments in biologic drug research, targeted immunotherapy, monoclonal antibody production, and drug delivery systems. Dupixent works by inhibiting interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling pathways, which play important roles in type 2 inflammation. Advances in biologic manufacturing, clinical research, and personalized treatment approaches are supporting the development of new therapeutic applications.

Regulatory and Legal Environment: The report considers regulations, FDA approvals, clinical trial requirements, pharmaceutical manufacturing standards, and healthcare reimbursement policies applicable to the U.S. Dupixent Market. The expansion of FDA-approved indications is creating opportunities for broader treatment adoption. Regulatory requirements concerning biologic drug safety, efficacy, and manufacturing quality also influence pharmaceutical companies and their operations.

Economic Factors: The study takes into account economic conditions such as healthcare expenditure, insurance coverage, prescription drug costs, patient affordability, and investment in pharmaceutical research and development. Coverage through commercial insurance, Medicare, and Medicaid, along with patient support programs, plays an important role in improving access to Dupixent treatment and supporting market growth.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/us-dupixent-market

Key Market Trends

The report highlights important developments in the U.S. Dupixent Market. It looks at the growing adoption of biologic therapies for chronic inflammatory diseases, increasing awareness of targeted treatments, and the expansion of FDA-approved indications. The growing preference for advanced biologic medications over conventional treatment options is supporting the adoption of Dupixent across different therapeutic areas.

The atopic dermatitis (AD) segment dominated the market by indication in 2024, as the condition remained the largest contributor to Dupixent sales in the United States. The hospital pharmacies segment held the largest share by distribution channel in 2024, supported by the role of hospitals and specialty healthcare facilities in managing high-cost biologic treatments.

The chronic obstructive pulmonary disease (COPD) segment is anticipated to register the highest growth rate during the forecast period, supported by the expansion of Dupixent's approved applications for patients with COPD and type 2 inflammation. Meanwhile, the retail pharmacies segment is expected to grow at the fastest rate as more patients transition toward long-term treatment and self-administered therapies.

The study considers how these changes are affecting market participants and their approach to clinical research, product development, indication expansion, distribution strategies, and changing patient requirements.

Competitive Landscape

The report identifies the major companies operating in the U.S. Dupixent Market. It provides an overview of their business operations, product offerings, and market presence. The study also covers recent company developments and strategies used to strengthen their positions in the market.

These strategies may include product development, clinical trials, regulatory approvals, strategic partnerships, research and development, and expansion into additional therapeutic indications. The report also examines competitive positioning, industry developments, and potential entry barriers that may affect competition.

Some of the key market players include:

Regeneron Pharmaceuticals, Inc. and Sanofi.

Market Segmentation

By Indication Outlook (Revenue – USD Billion, 2020–2034)
Atopic Dermatitis (AD)
Asthma
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Chronic Obstructive Pulmonary Disease (COPD)
Others

By Distribution Channel Outlook (Revenue – USD Billion, 2020–2034)
Hospital Pharmacies
Retail Pharmacies
Others

The Report Answers Questions Such As

• What is the current size of the U.S. Dupixent Market?
• What is the projected market size by the end of the forecast period?
• What CAGR is expected during the forecast period from 2025 to 2034?
• What factors are influencing the growth of the U.S. Dupixent Market?
• What are the major trends shaping the Dupixent industry?
• Which indication segment accounts for the largest market share?
• Which indication segment is expected to grow at the fastest rate?
• Which distribution channel accounts for the largest market share?
• Which distribution channel is expected to register the fastest growth?
• What role do FDA approvals play in the expansion of the U.S. Dupixent Market?
• Who are the leading companies operating in the U.S. Dupixent Market?
• What opportunities are available to existing and new market participants?

More Trending Latest Reports By Polaris Market Research:

Boot Market Share

Regenerative Meat Market Growth

Outdoor Advertising Market Forecast

Electric Fencing Market Analysis

Recloser Market Opportunities

Airport Services Market Trends

Hearing Loss Disease Treatment Market Size

Hyperautomation Market Share

LNG Storage Tanks Market Growth

Directed Energy Weapons Market Forecast